This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in other viral infections기타 바이러스감염을 유발한 HIV 감염병 (HIV 기타바이러스감염증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: B20.3 (HIV disease resulting in other viral infections) | Special Copayment Reduction: V103 (serious illness related to HIV infection, 10% copayment for 5 years after registration)
B. SynonymsHIV-associated other viral infections; HIV-associated herpes infection; HIV-associated herpes zoster; HIV-associated EBV lymphoma; HIV-HPV disease; AIDS-associated viral infections
C. Adult onsetLikelihood of first onset in adulthood: Very high — Herpes zoster (VZV), HSV ulcers, EBV-associated lymphoma, and HPV-associated disease all occur mainly in adult patients with HIV, with high frequency especially in adults (30s-60s) whose immunosuppression has progressed.
1. History1981: after the description of AIDS, recognition of increased HSV, VZV, EBV, and HPV infections → 1990s: pathogenesis of AIDS-related lymphoma elucidated → 1996: decrease in opportunistic viral infections after ART → 2000s: increase in HPV-associated anal cancer noted → 2006: VZV vaccine (Zostavax) licensed; 2017: recombinant VZV vaccine (Shingrix) licensed.
2. CausesMain pathogens: HSV-1/2 (oral and genital ulcers), VZV (herpes zoster), EBV (lymphoma, oral hairy leukoplakia), HPV (genital warts, anal and cervical cancer), HHV-8 (Kaposi sarcoma, primary effusion lymphoma). CD4 decline is the common mechanism of reactivation and malignant transformation.
3. GeneticsHLA genotype influences the efficiency of the immune response to HSV and VZV. HHV-8 Kaposi development: association with KIR3DL1/LILRB1 genotypes. EBV lymphoma: c-MYC translocation (Burkitt lymphoma). HPV carcinogenesis: inactivation of p53 and Rb (E6 and E7 proteins). Unlike ganciclovir resistance, HSV acyclovir resistance: TK (UL23), DNA Pol mutations.
4. General epidemiologyIn patients with HIV, the risk of herpes zoster is 3 to 13 times that of the general population. Recurrence and persistence of HSV ulcers increase markedly when CD4 declines. The risk of anal cancer in patients with HIV is 80 to 90 times that of the general population (HPV). EBV-associated lymphoma: AIDS-defining illness. In Korean patients with HIV, herpes zoster and HPV-associated disease are important complications.
5. PathophysiologyCD4 T-cell depletion → loss of herpesvirus-specific CTLs → reactivation of HSV, VZV, and EBV. EBV and HHV-8: tumor formation in latently infected B cells and endothelial cells (cancer-causing proteins such as EBER, LMP, LANA). HPV: E6 (p53 degradation), E7 (Rb inactivation) → cell cycle abnormality → cancer development. The HIV Tat protein itself promotes HHV-8 replication.
6. SymptomsHSV: painful oral and genital ulcers (recurrent, persistent). VZV herpes zoster: dermatomal vesicular rash, pain. EBV: oral hairy leukoplakia, lymphoma (fever, lymphadenopathy, night sweats, weight loss). HPV: genital warts, anal lesions. HHV-8: Kaposi sarcoma (purple lesions of skin, mucosa, and viscera).
7. SignsHSV: PCR or culture positive. VZV: dermatomal vesicles (dermatomal distribution). EBV oral hairy leukoplakia: EBV PCR positive; white corrugated lesion on the lateral tongue (cannot be wiped off, unlike Candida). Lymphoma: lymphadenopathy on CT, EBER positive on biopsy. HPV anal cancer: anal HRA (high-resolution anoscopy), tissue biopsy.
8. ScreeningHPV-related screening: anal cytology (anal Pap) or high-resolution anoscopy (HRA) — regular (every 1-3 years) screening recommended for MSM (men who have sex with men) with HIV. Cervical cytology (Pap test) — annually in HIV-positive women. Consider VZV vaccination for persons who have not formed VZV antibodies. HSV serologic testing is adjunctive. No screening for EBV lymphoma (evaluate when symptoms occur).
9. DiagnosisHSV: PCR (lesion swab), direct immunofluorescence, or viral culture. VZV: clinical diagnosis (typical skin findings) or PCR. EBV lymphoma: biopsy (EBER immunohistochemistry, c-MYC FISH). HPV-associated lesions: tissue biopsy, HPV genotyping. HHV-8 KS: clinical and histologic (spindle cells, HHV-8 LANA staining).
10. TreatmentHSV: acyclovir/valacyclovir (mild), IV acyclovir (severe). VZV herpes zoster: acyclovir 800 mg 5 times daily or valacyclovir 1 g 3 times daily × 7-10 days. EBV lymphoma: CHOP/R-CHOP + ART. HPV anal cancer: radiation ± chemotherapy. HHV-8 KS: ART first, paclitaxel and liposomal doxorubicin.
11. PrognosisHSV and VZV: mostly controllable with ART and antivirals. EBV lymphoma: some cured with chemotherapy combined with ART. HPV-associated cancer: good prognosis if detected early. HHV-8 KS: improves after ART, but poor with visceral involvement. Multidrug-resistant HSV (TK mutations) is difficult to treat.
12. PreventionRecombinant VZV vaccine (Shingrix) is recommended for patients with HIV and CD4 >200/μL. HPV vaccine (quadrivalent or 9-valent) is recommended for patients with HIV under age 26, and under age 45 in some guidelines. Long-term suppressive therapy with acyclovir/valacyclovir when HSV recurs frequently. Maintain CD4 with ART. Condom use reduces HSV and HPV transmission.
13. ReferencesPanel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections. AIDSinfo. 2023 … and 9 other papers

1. History

With the HIV/AIDS epidemic, an increase in other viral infections, especially herpesvirus family and HPV-associated diseases, was recognized. Since AIDS was first described in 1981, evidence rapidly accumulated that herpes simplex virus (HSV) ulcers, herpes zoster (VZV), oral EBV infection (oral hairy leukoplakia), HPV-associated genital warts and cancer, and HHV-8-associated Kaposi sarcoma are markedly increased in patients with HIV.

From the mid-1980s, AIDS-related Kaposi sarcoma (KS) was recognized as a representative clinical hallmark of AIDS, and in 1994 Chang et al. established by molecular biology that its cause is HHV-8 (Kaposi sarcoma-associated herpesvirus, KSHV). The role of EBV in the pathogenesis of AIDS-related lymphoma was elucidated in the 1990s, and it was established that the EBV-positive rate is high especially in central nervous system lymphoma, Burkitt lymphoma, and diffuse large B-cell lymphoma.

Regarding HPV-associated disease, epidemiologic studies published from the 1990s showed that the risk of anal cancer, cervical cancer, and head and neck cancer in patients with HIV is markedly higher than in the general population. Even after the introduction of ART, the risk of HPV-associated cancer has not decreased or has even tended to increase (because prolonged survival provides sufficient time for HPV carcinogenesis), and the importance of screening for HPV-associated cancer in patients with HIV is being emphasized.

In 2006 the VZV (herpes zoster) live vaccine (Zostavax) was licensed but had safety concerns in immunocompromised patients, and in 2017 the recombinant subunit VZV vaccine (Shingrix) was licensed, making herpes zoster prevention possible that can be used safely even in the immunocompromised state.


2. Causes

B20.3 encompasses HIV-associated infections and complications caused by other viruses, excluding CMV. The main pathogens are as follows.

Herpes simplex virus (HSV-1, HSV-2): Repeatedly causes painful ulcers of the oral (mainly HSV-1) and genital (mainly HSV-2) mucosa and skin. In patients with HIV, ulcers are larger and last longer, and can disseminate to visceral organs such as the esophagus, bronchi, lungs, and brain. HSV mucosal ulcers lasting 1 month or longer are an AIDS-defining illness in the 1993 CDC definition.

Varicella-zoster virus (VZV): After childhood varicella infection, it lies latent in dorsal root ganglia and elsewhere and reactivates during immunosuppression to cause herpes zoster. The incidence in patients with HIV is 3 to 13 times higher than in the general population, and serious complications such as multidermatomal or disseminated herpes zoster, chronic VZV ulcers, and varicella VZV retinal necrosis (ARN, PORN) may occur.

Epstein-Barr virus (EBV, HHV-4): Oral EBV reactivation causes oral hairy leukoplakia. In the immunosuppressed state, EBV plays an important role in the pathogenesis of AIDS-related lymphoma (Burkitt lymphoma, diffuse large B-cell lymphoma, primary CNS lymphoma, body cavity lymphoma).

Human papillomavirus (HPV): Among the various subtypes, low-risk types (HPV 6, 11) cause genital warts and anal condyloma acuminatum, and high-risk types (HPV 16, 18, 31, 33, etc.) cause cervical cancer, anal cancer, and head and neck cancer (oropharyngeal cancer). The risk of HPV-associated cancer is markedly increased in patients with HIV.

HHV-8 (Kaposi sarcoma-associated herpesvirus, KSHV): The cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman disease (MCD).


3. Genetics

Host genetic factors related to other viral infections vary according to the type of virus.

Genes of the TLR3, TLR9, IRF3, and STING pathways are involved in the immune response to HSV, and rare genetic defects in these pathways can underlie HSV encephalitis. An association between herpes simplex virus type 1 encephalitis and defects in the TLR3, UNC93B1, TRIF (TICAM1), and TBK1 genes has been reported in children and young adults.

NK cells play an important role in controlling VZV, and some studies suggest that polymorphisms in NK cell receptor genes (NKG2D, NKG2A) affect susceptibility to VZV reactivation. HLA genotype is also related to the efficiency of VZV-specific T-cell responses.

In EBV-associated lymphoma, viral genetics is important. EBV latency genes (EBNA1-6, LMP1, LMP2) are directly involved in B-cell immortalization and lymphoma development. In Burkitt lymphoma, c-MYC translocation (most commonly t(8;14), or t(2;8), t(8;22)) is the core oncogenic mechanism.

The role of the viral E6 and E7 proteins is central in HPV carcinogenesis. E6 degrades p53 via the ubiquitin-proteasome pathway to inhibit apoptosis, and E7 inactivates Rb to abnormally promote progression through the S phase of the cell cycle. Integration of HPV DNA into the host genome is important in the carcinogenic process, and p16INK4a overexpression is used as a surrogate marker of HPV integration.


4. General epidemiology

The incidence of other viral infections in patients with HIV is markedly higher than in the general population, and the specific figures vary according to the type of virus.

The annual incidence of herpes zoster (VZV reactivation) in patients with HIV is 3 to 13 times higher than in the general population. The risk is higher at CD4 <200/μL, and even after ART the risk of herpes zoster remains higher than in the general population. In Korea as well, herpes zoster is recognized as an important complication in patients with HIV.

Persistent and recurrent HSV ulcers are common in patients with HIV and CD4 <200/μL, and chronic ulcers persist if untreated. Genital HSV-2 infection is known to increase HIV transmission 2- to 5-fold, so it is also important in HIV epidemiology.

The risk of anal cancer in patients with HIV is 80 to 90 times higher than in the general population, and is particularly high in men who have sex with men (MSM) with HIV. Cervical precancer (CIN 2/3) and cervical cancer also occur at markedly higher rates in HIV-positive women. Since ART, other AIDS-defining illnesses have decreased, but HPV-associated cancers show a paradoxical trend of actually increasing because of prolonged survival.

Kaposi sarcoma (HHV-8) was the most common AIDS-defining malignancy in patients with AIDS before ART, but has decreased by more than 80% since ART. EBV-associated lymphoma (non-Hodgkin lymphoma) occurs 100 to 500 times more often in patients with HIV than in the general population, and is an AIDS-defining illness.


5. Pathophysiology

The common mechanism of the increased vulnerability to other viral infections caused by HIV is reduced cell-mediated immunity due to CD4+ T-cell depletion. The pathophysiology for each virus is described below.

HSV/VZV reactivation: HSV-1, HSV-2, and VZV all exist in a latent state in ganglion neurons after primary infection. CD4+ T cells (especially virus-specific CD8+ CTLs) monitor the latent virus and suppress reactivation. When this surveillance function is weakened by HIV-induced CD4 T-cell depletion, the virus reactivates and symptomatic infection occurs. In patients with HIV, HSV reactivation shows an inverse relationship with the CD4 count.

EBV-associated lymphoma: EBV lies latent in B lymphocytes and expresses latency proteins such as EBNA1, EBNA2, LMP1, and LMP2, inducing B-cell immortalization. Under normal immunity, EBV-specific CTLs monitor and eliminate EBV-infected B cells. When EBV-specific CTL function declines because of HIV-induced CD4 T-cell depletion, EBV-infected B cells escape immune surveillance and become immortalized and malignant. LMP1 activates the NF-κB and MAPK/ERK pathways, promoting B-cell proliferation and survival.

HPV carcinogenesis: HPV E6 forms a complex with E6AP (an E3 ubiquitin ligase) to degrade p53, and E7 inactivates the Rb protein, disabling cell cycle regulation. HPV carcinogenesis is rapid in patients with HIV because HPV-specific immune surveillance declines with CD4 T-cell depletion, and the HIV Tat protein is explained to weaken the HPV E2 repressor function.

HHV-8/KS: HHV-8 latency proteins such as LANA (latency-associated nuclear antigen), vFLIP, and vCyclin inhibit apoptosis and promote cell proliferation. The HIV Tat protein directly promotes HHV-8 lytic replication, and immune control of HHV-8 is weakened by CD4 T-cell depletion.


6. Symptoms

HSV infection: In patients with HIV, oral or genital herpes simplex recurs more frequently, and ulcers are larger and deeper and last longer. HSV mucosal ulcers lasting 1 month or longer are an AIDS-defining illness. Severe HSV esophagitis (painful swallowing, chest pain), HSV pneumonia (cough, dyspnea), and HSV encephalitis (headache, fever, altered consciousness, seizures) may occur.

Herpes zoster (VZV): Characterized by dermatomal pain and a vesicular rash. In patients with HIV, multidermatomal herpes zoster and disseminated herpes zoster (involving systemic skin or viscera) are more common, and postherpetic neuralgia (PHN) lasts longer. If VZV retinal necrosis (ARN, PORN) develops in ophthalmic zoster, abrupt vision loss may result.

EBV-associated disease: Oral hairy leukoplakia presents as a white corrugated lesion on the side of the tongue that cannot be removed. AIDS-related lymphoma presents with fever, night sweats, weight loss (B symptoms), lymphadenopathy, or symptoms of CNS involvement (headache, altered consciousness).

HPV-associated disease: Genital warts (condyloma acuminatum), anal lesions (anal intraepithelial neoplasia, anal cancer), cervical intraepithelial neoplasia (CIN). Anal cancer may present with bloody stool, anal pain, or an anal mass.

Kaposi sarcoma (HHV-8): Multiple purple-brown macules, nodules, and plaques appear on the skin, and the oral mucosa, viscera (lung, gastrointestinal tract), and lymph nodes may be involved. Pulmonary KS causes dyspnea, cough, and hemoptysis.


7. Signs

HSV: The clinical finding of vesicle → ulcer is typical. PCR (lesion swab or CSF) is the gold standard for diagnosis. Culture can also be used but is less sensitive than PCR. Direct immunofluorescence (DFA) is used for rapid diagnosis. When resistant HSV (acyclovir resistance with TK mutation) is suspected, perform acyclovir susceptibility testing.

VZV herpes zoster: The dermatomal vesicular rash is clinically typical, so most cases can be diagnosed clinically. For atypical findings (disseminated, non-vesicular, chronic ulcer), confirm VZV DNA by PCR (lesion swab or CSF).

EBV lymphoma: Lymphadenopathy, splenomegaly, and peritoneal lesions on chest, abdominal, and pelvic CT. PET-CT is useful for staging and assessing treatment response. A positive EBER (EBV-encoded small RNA) reaction on tissue biopsy is the standard diagnostic criterion for EBV-associated lymphoma. c-MYC FISH and immunophenotypic classification (CD20, CD10, BCL6, BCL2, MYC, etc.) are needed for lymphoma subtype classification.

HPV-associated lesions: Anal intraepithelial neoplasia (AIN) and anal cancer are diagnosed with anoscopy + anal cytology (anal Pap), and high-resolution anoscopy (HRA) + biopsy. Cervical cytology (Pap smear) + HPV genotyping + colposcopic biopsy.

KS: Characteristic purple skin lesions are clinically suggestive, and the diagnosis is confirmed by HHV-8 LANA immunostaining on biopsy.


8. Screening

Screening for HPV-associated cancer is the most important screening test in patients with HIV. In HIV-positive women, cervical cytology (Pap test) + HPV test is performed at the first visit and annually thereafter (more often than in the general population). In men who have sex with men (MSM) with HIV, anal cytology or high-resolution anoscopy (HRA) at 1- to 3-year intervals is recommended.

VZV antibody screening: In patients with HIV who are VZV antibody negative (no history of childhood varicella or vaccination), perform a VZV antibody test, and if antibody negative and CD4 >200/μL, consider varicella vaccine or recombinant VZV vaccine (Shingrix).

There is no general screening test for EBV lymphoma, HSV, or VZV, and the realistic strategy is prompt evaluation when clinical symptoms occur.


9. Diagnosis

Diagnosis of HSV: PCR has the highest sensitivity and specificity across various specimens such as lesion swab (base of the lesion), CSF, and BAL (sensitivity ~98%, specificity ~99%). Viral culture is slower and less sensitive than PCR but is needed for resistance testing. HSV-1 and HSV-2 types are distinguished by PCR genotyping.

Diagnosis of VZV herpes zoster: Diagnosed by typical clinical findings. For atypical findings, detect VZV DNA by PCR (lesion swab). When meningitis or encephalitis is suspected, CSF VZV PCR.

Diagnosis of EBV lymphoma: Tissue biopsy is essential, and EBER immunohistochemistry and in situ hybridization (ISH) are the confirmatory criteria for EBV-associated lymphoma. Subtype classification by lymphoma immunophenotype, c-MYC FISH, and other molecular tests. CSF cytology and EBV PCR are used to differentiate CNS lymphoma.

Diagnosis of HPV-associated lesions: Cervical cancer: Pap test + HPV test → colposcopy + biopsy if abnormal. Anal cancer/AIN: anal Pap or HRA + biopsy + HPV genotyping. Genital warts: clinical diagnosis (can be confirmed after applying acetic acid).


10. Treatment

Treatment of HSV: Mild: acyclovir 400 mg 3 times daily or valacyclovir 1 g twice daily × 7-10 days. Severe/disseminated HSV: acyclovir 5-10 mg/kg IV 3 times daily × 14-21 days. HSV esophagitis: IV acyclovir or oral valacyclovir for 2-3 weeks. For acyclovir resistance (TK mutation): IV foscarnet (foscarnet 40 mg/kg 3 times daily or 60 mg/kg twice daily). Suppressive therapy to prevent recurrence: long-term acyclovir 400 mg twice daily or valacyclovir 500 mg once daily.

Treatment of VZV herpes zoster: Acyclovir 800 mg orally 5 times daily × 7-10 days or valacyclovir 1 g 3 times daily × 7-10 days. Severe or disseminated VZV: acyclovir 10-15 mg/kg IV 3 times daily × 10-14 days or more. VZV retinitis (ARN, PORN): IV acyclovir + intravitreal ganciclovir/foscarnet + early initiation of ART.

Treatment of EBV lymphoma: AIDS-related non-Hodgkin lymphoma: R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) ± ART. Primary CNS lymphoma: high-dose methotrexate + whole-brain radiation therapy + ART. Burkitt lymphoma: intensive chemotherapy with EPOCH or CODOX-M/IVAC.

Treatment of KS: Starting ART is the key to KS treatment. Localized cutaneous KS may improve with ART alone. KS with extensive skin or visceral involvement: liposomal doxorubicin or IV paclitaxel. Pulmonary KS: chemotherapy + ART.


11. Prognosis

The prognosis of other viral infections varies according to the type of infection and immune status.

HSV and VZV infections can mostly be controlled with appropriate antiviral treatment and ART, but treatment becomes difficult when resistant virus (TK-mutant HSV) develops. VZV retinal necrosis leads to permanent vision loss if diagnosis is delayed.

The prognosis of AIDS-related lymphoma has improved with the combination of ART and chemotherapy. In diffuse large B-cell lymphoma treated with R-CHOP, the complete remission rate is about 50-70%, and the 5-year survival rate has improved greatly compared with the pre-ART era. Primary CNS lymphoma still has a poor prognosis.

HPV-associated cancers (anal cancer, cervical cancer) have a good prognosis when detected early. However, in advanced anal cancer or cervical cancer, the prognosis is limited even with standard treatment. As survival is prolonged after ART, HPV-associated cancer may become an important cause of death in patients with HIV in the long term.

After ART, more than 80% of cutaneous KS goes into remission or improves greatly. However, visceral KS (especially pulmonary KS) still has a poor prognosis.


12. Prevention

VZV vaccination: Recombinant VZV vaccine (Shingrix, RZV) is recommended as 2 doses (at 0 and 2-6 months) for HIV-positive adults with CD4 >200/μL. The live vaccine Zostavax is contraindicated in immunocompromised patients because of the risk of disseminated VZV.

HPV vaccination: HPV 9-valent vaccine (Gardasil 9) is given as 3 doses to HIV-positive men and women aged 26 or younger. Some guidelines (US ACIP) recommend that HPV vaccine may also be considered in patients with HIV aged 27-45. Condom use partially reduces HPV and HSV transmission.

HSV suppressive therapy: In patients with HIV who have 6 or more genital HSV recurrences per year, long-term suppressive therapy with acyclovir or valacyclovir is given to prevent recurrence and reduce the risk of HIV transmission.

ART and CD4 maintenance: Maintaining the CD4 count through ART is fundamental to preventing complications associated with all herpesviruses and HPV. When CD4 >200/μL is maintained, the risk of HSV and VZV reactivation, EBV lymphoma, and KS decreases markedly.


13. References

  1. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. AIDSinfo. Updated 2023. Available at: clinicalinfo.hiv.gov.

  2. Guiguet M, Boué F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152-1159. DOI: 10.1016/S1470-2045(09)70282-7. PMID: 19880066.

  3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338(13):853-860. DOI: 10.1056/NEJM199803263381301. PMID: 9516219.

  4. Silverberg MJ, Chao C, Leyden WA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS. 2009;23(17):2337-2345. DOI: 10.1097/QAD.0b013e3283319184. PMID: 19741479.

  5. Bower M, Dalla Pria A, Coyle C, et al. Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma. J Clin Oncol. 2014;32(5):409-414. DOI: 10.1200/JCO.2013.51.6757. PMID: 24395846.

  6. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. DOI: 10.1200/JCO.2013.54.8800. PMID: 25113753.

  7. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500-1510. DOI: 10.1093/jnci/92.18.1500. PMID: 10995805.

  8. Whitley RJ, Gnann JW. Herpes zoster: focus on treatment. Antiviral Res. 2022;201:105296. DOI: 10.1016/j.antiviral.2022.105296. PMID: 35288288.

  9. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487-2498 (see immune recovery timing). DOI: 10.1056/NEJMoa1312884. PMID: 24963568.

  10. Korean Society for AIDS; Korean Society of Infectious Diseases. Korean Guidelines for Diagnosis and Treatment of HIV/AIDS. Infect Chemother. 2021;53(4):e54. DOI: 10.3947/ic.2021.0091. PMID: 34910839.